Literature DB >> 34016833

Hesperetin regulates transforming growth factor-β1/Smads pathway to suppress epithelial-mesenchymal transition -mediated invasion and migration in cervical cancer cell.

Jing Wang1,2, Han Chen1, Zhiqiang Hu3, Kang Ma1, Hui Wang4.   

Abstract

Hesperetin is an abundant flavonoid in citrus fruits, and be confirmed to possess a chemo-preventive effect on cancer. Migration and invasion are the main causes of death of cervical cancer patients, in which epithelial-mesenchymal transition (EMT) can directly contribute to malignant phenotypes of tumor cells. The present study aims to investigate the inhibitory effect of hesperetin on EMT-mediated invasion and migration in cervical cancer cells through transforming growth factor-β1 (TGF-β1)/Smads pathway. Cell viability, cell migration and invasion ability, and cell morphology were evaluated and monitored using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assays, Transwell assays and optical microscope, respectively. The change of EMT marker protein E-cadherin and N-cadherin was assessed by immunofluorescence assay, whereas the protein expression of EMT bio-marker and TGF-β1/Smads pathway were detected through western blot analysis. In conclusion, hesperetin can suppress EMT-mediated invasion and migration of cervical cancer cells by inhibiting abnormal activation of TGF-β1/Smads pathway. The study provides an experimental basis for the prevention of the invasion and migration of cervical cancer.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34016833     DOI: 10.1097/CAD.0000000000001085

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  1 in total

1.  Hesperetin ameliorates glioblastoma by inhibiting proliferation, inducing apoptosis, and suppressing metastasis.

Authors:  Qian Cheng; Lianzhi Mao; Hongxiang Huang; Longguang Tang; Hongyan Jiang; Yufei Zhang; Qingchun Mu
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.